February 21, 2025 07:24 AM ESTUpdated 09:17 AM

Pfizer ends rollout of Beqvez, putting another dent in hemophilia gene therapy field

Kyle LaHucik

Senior Reporter

Pfizer is ending the development and commercialization of its hemophilia B gene therapy Beqvez, the company confirmed in an emailed statement to Endpoints News. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer ends rollout of Beqvez, putting another dent in hemophilia gene therapy field

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Pfiz­er ends roll­out of Be­qvez, putting an­oth­er dent in he­mo­phil­ia gene ther­a­py field

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Pfizer ends rollout of Beqvez, putting another dent in hemophilia gene therapy field